<DOC>
	<DOCNO>NCT01033656</DOCNO>
	<brief_summary>An open , randomize , parallel-group , comparative , multicentre study . Patients corticosteroid ( plus conventional therapy ) randomize receive anakinra ( Kineret® ) , one following : methotrexate , azathioprine , leflunomide , cyclosporin A sulphasalazine . Patients enter study consider refractory corticosteroid ( prednisolone equivalent ≥10 mg/day ) time randomization . The randomized phase study follow open-label extension ( OLE ) phase , follow-up drug survival , efficacy , tolerability disease-related parameter long-term treatment anakinra one study DMARDs combination study drug additional 28 week .</brief_summary>
	<brief_title>Treatment Refractory Adult-onset Still 's Disease With Anakinra : Randomized Study</brief_title>
	<detailed_description>Product : Kineret ( anakinra ) Comparative agent : Methotrexate azathioprine leflunomide cyclosporin A sulphasalazine Protocol title : An open , randomize study treat refractory adult-onset Still 's disease IL-1ra anakinra ( Kineret , compare establish , single anti-rheumatic treatment Target Disease : Adult-onset Still 's disease Patients : 23 patient diagnosed AOSD , live four Nordic country . Study Objectives : To follow change clinical status disease activity patient receive anakinra , compare treat establish DMARD , addition corticosteroid patient refractory AOSD . To compare change disease-related parameter ( global health , patient 's assessment disease , laboratory value ) two randomized group . To assess safety anakinra AOSD . To follow-up drug survival , efficacy , tolerability disease-related parameter long-term treatment AOSD ( open phase ) .</detailed_description>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<mesh_term>Still 's Disease , Adult-Onset</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Azathioprine</mesh_term>
	<mesh_term>Leflunomide</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<criteria>Must diagnose AOSD accord preliminary classification Yamaguchi ( 1992 ) . Other disease similar symptom must exclude . Has expose corticosteroid ≥2 month prior randomization AOSD . Needs prednisolone dose ≥10 mg/day equivalent , yet unacceptable disease activity determine investigator . AntiTNF agent must discontinue 4 8 week prior commence study medication . Use corticosteroid ( prednisolone equivalent &lt; 10 mg/day . History recurrent chronic infection , include : tuberculosis malignancy major chronic inflammatory disease syndrome drug alcohol abuse know positivity hepatitis B , C HIV . Use antiTNF agent ≤4 week ( etanercept ) or≤8 week ( infliximab adalimumab ) prior randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>adult-onset Still 's disease</keyword>
	<keyword>anakinra</keyword>
	<keyword>prednisolone</keyword>
	<keyword>disease-modifying antirheumatic drug</keyword>
	<keyword>methotrexate</keyword>
	<keyword>efficacy</keyword>
	<keyword>patient</keyword>
</DOC>